

# Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

NCT06569147

---

|                   |                              |
|-------------------|------------------------------|
| <b>Status</b>     | RECRUITING                   |
| <b>Phase</b>      | Phase 1, Phase 2             |
| <b>Sponsor</b>    | Brigham and Women's Hospital |
| <b>Enrollment</b> | 49 participants              |

## Key Eligibility Criteria

---

### Inclusion (14)

- Previously diagnosed with AL amyloidosis based on IMWG criteria who have relapsed or refractory disease after treatment with at least one prior line of therapy (minimum 2 cycles).
- Participants must have progression of light chain disease, defined as dFLC  $\geq 20$ mg/L.
- For Phase 2 only, measurable hematologic disease, satisfying one of the following criteria: Difference between involved and uninvolved free light chain (FLC) over 40 mg/L; Abnormal level of FLC with an abnormal  $\kappa/\lambda$  ratio (except in participants with CKD stage 3 or higher where a rise of lambda FLC to an abnormal level and of at least 50% over the nadir with a normal  $\kappa/\lambda$  ratio is acceptable); A serum M spike measuring  $\geq 0.5$  g/dL
- Age  $\geq 18$  years
- ECOG performance status  $\leq 2$  or Karnofsky  $\geq 60\%$
- ... and 9 more (see full listing online)

### Exclusion (23)

- Prior BCMA-targeting bispecific antibodies or BCMA-targeting CAR-T therapy.
- Participants refractory to belantamab mafodotin OR participants that have received belantamab as the immediate past line of therapy.
- Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities  $\geq$  Grade 1) with the exception of alopecia.
- Participants who are receiving any other investigational agents for this condition.
- Participants with Stage IIIB Amyloidosis as defined by the 2004 Mayo Clinic Criteria (see above).
- ... and 18 more (see full listing online)

## Locations (1 total)

---

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

---

<https://clinicaltrials.gov/study/NCT06569147>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.